US$13bn+ of ebit growing a few percent a year plus US$10bn and change free cash flow yield (and a dividend/share repurchase combination greater than this)...
...and positive organic volume and pricing across-the-board:
I would suggest about a US$156bn (x12 ebit multiple) to US$200bn (5% free cash flow yield) valuation.
Well Procter & Gamble - the company whose results the above metrics are taken from - has an EV of about US$237bn currently. Even trying to adjust the above numbers for the 5%+ return to shareholders or future growth in line with the guidance below struggles to justify the current share price unless you really pay up for relative stability and near-term income.
Otherwise in quite interesting news, the company is also focusing its brand portfolio a little further. Sensible stuff along with the ongoing cost control programme...but does not really move the needle materially for me.
With the share pushing US$80 today my feeling is that the company remains a range-bound higher yielding bond equivalent. Buying at US$76, selling at US$84 puts a US$80 share price right in the middle of the range. If you hold it already or enjoy dividends then fine, otherwise better alpha scope rests elsewhere.